Formulary guidance and transparency from P&T to point of care


Reality Check on Hemophilia A or B With Inhibitors

Market access for hemophilia A or B with inhibitors treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 45% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In April 2020, the FDA approved Laboratoire Francais du Fractionnement et des Biotechnologies S.A.'s Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes in people at least 12 years old with hemophilia A or B with inhibitors
  • Key Findings: Health plans are not differentiating hemophilia A or B with inhibitor products. There is minimal contracting for this class. Competition is expected to grow with longer-acting products entering the market

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.